Aardvark Therapeutics, Inc. is a clinical‐stage biopharmaceutical company that specializes in the discovery and development of RNA‐based aptamer therapies. Founded by a team of nucleic acid experts, the company has built a proprietary aptamer discovery and optimization platform designed to generate highly specific, novel drug candidates. Aardvark’s scientific approach focuses on harnessing the unique binding properties of aptamers to target pathways involved in vascular, ocular and inflammatory diseases.
The company’s lead programs include two clinical‐stage candidates for ophthalmology indications such as neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME). These therapeutics leverage modified oligonucleotides to achieve extended half‐lives and improved tissue penetration. In addition, Aardvark maintains a robust preclinical pipeline with programs aimed at cardiovascular disease and pulmonary disorders, where aptamer technology offers the potential for precise modulation of disease‐related proteins.
Aardvark Therapeutics is headquartered in Cleveland, Ohio, with a research hub in Cambridge, Massachusetts, and maintains strategic partnerships with academic institutions and contract research organizations across North America and Europe. The company went public on the Nasdaq in 2022 and has since expanded its in‐house capabilities, including chemistry, manufacturing and controls (CMC) operations and translational medicine functions to accelerate its clinical development milestones.
Under the leadership of Chief Executive Officer Dr. Robert Rosen and Chief Scientific Officer Dr. Angela Smith, Aardvark’s management team brings decades of experience in oligonucleotide drug development, regulatory strategy and commercialization. The company continues to advance its programs through Phase 2 studies, while exploring additional indications and collaborations to extend its pipeline and maximize the therapeutic potential of its aptamer platform.
AI Generated. May Contain Errors.
